nodes	percent_of_prediction	percent_of_DWPC	metapath
Clopidogrel—Peripheral ischaemia—Varenicline—nicotine dependence	0.0379	0.0565	CcSEcCtD
Clopidogrel—Drug hypersensitivity—Varenicline—nicotine dependence	0.0343	0.0512	CcSEcCtD
Clopidogrel—Gastric ulcer—Varenicline—nicotine dependence	0.0238	0.0355	CcSEcCtD
Clopidogrel—Platelet count decreased—Varenicline—nicotine dependence	0.0232	0.0347	CcSEcCtD
Clopidogrel—CYP2B6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0199	0.0602	CbGpPWpGaD
Clopidogrel—Menorrhagia—Varenicline—nicotine dependence	0.0187	0.0279	CcSEcCtD
Clopidogrel—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0168	0.051	CbGpPWpGaD
Clopidogrel—CYP2B6—Fatty acids—CYP2A7—nicotine dependence	0.0155	0.047	CbGpPWpGaD
Clopidogrel—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.015	0.0455	CbGpPWpGaD
Clopidogrel—Pulmonary embolism—Varenicline—nicotine dependence	0.0138	0.0206	CcSEcCtD
Clopidogrel—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0137	0.0415	CbGpPWpGaD
Clopidogrel—Influenza like illness—Varenicline—nicotine dependence	0.0134	0.02	CcSEcCtD
Clopidogrel—Oesophagitis—Varenicline—nicotine dependence	0.0126	0.0188	CcSEcCtD
Clopidogrel—CYP2B6—Xenobiotics—CYP2A7—nicotine dependence	0.0123	0.0373	CbGpPWpGaD
Clopidogrel—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.012	0.0365	CbGpPWpGaD
Clopidogrel—Deafness—Varenicline—nicotine dependence	0.0112	0.0167	CcSEcCtD
Clopidogrel—Eczema—Varenicline—nicotine dependence	0.0112	0.0167	CcSEcCtD
Clopidogrel—CES1—E2F transcription factor network—WASF1—nicotine dependence	0.0109	0.0332	CbGpPWpGaD
Clopidogrel—Injury—Varenicline—nicotine dependence	0.0109	0.0163	CcSEcCtD
Clopidogrel—Renal failure acute—Varenicline—nicotine dependence	0.0109	0.0162	CcSEcCtD
Clopidogrel—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.0104	0.0316	CbGpPWpGaD
Clopidogrel—Arthritis—Varenicline—nicotine dependence	0.0103	0.0154	CcSEcCtD
Clopidogrel—Hypoglycaemia—Varenicline—nicotine dependence	0.0103	0.0153	CcSEcCtD
Clopidogrel—Osteoarthritis—Varenicline—nicotine dependence	0.01	0.015	CcSEcCtD
Clopidogrel—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.01	0.015	CcSEcCtD
Clopidogrel—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.0093	0.0282	CbGpPWpGaD
Clopidogrel—Liver function test abnormal—Varenicline—nicotine dependence	0.00927	0.0138	CcSEcCtD
Clopidogrel—Abdominal pain upper—Varenicline—nicotine dependence	0.00917	0.0137	CcSEcCtD
Clopidogrel—P2RY12—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00902	0.0274	CbGpPWpGaD
Clopidogrel—Gastritis—Varenicline—nicotine dependence	0.00888	0.0133	CcSEcCtD
Clopidogrel—Abdominal distension—Varenicline—nicotine dependence	0.00873	0.013	CcSEcCtD
Clopidogrel—Asthma—Varenicline—nicotine dependence	0.00868	0.0129	CcSEcCtD
Clopidogrel—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00848	0.0257	CbGpPWpGaD
Clopidogrel—Angina pectoris—Varenicline—nicotine dependence	0.00845	0.0126	CcSEcCtD
Clopidogrel—Bronchitis—Varenicline—nicotine dependence	0.00834	0.0124	CcSEcCtD
Clopidogrel—Depression—Varenicline—nicotine dependence	0.00771	0.0115	CcSEcCtD
Clopidogrel—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00767	0.0114	CcSEcCtD
Clopidogrel—Stomatitis—Varenicline—nicotine dependence	0.00754	0.0112	CcSEcCtD
Clopidogrel—Conjunctivitis—Varenicline—nicotine dependence	0.00752	0.0112	CcSEcCtD
Clopidogrel—Hepatobiliary disease—Varenicline—nicotine dependence	0.00732	0.0109	CcSEcCtD
Clopidogrel—Epistaxis—Varenicline—nicotine dependence	0.0073	0.0109	CcSEcCtD
Clopidogrel—Sinusitis—Varenicline—nicotine dependence	0.00726	0.0108	CcSEcCtD
Clopidogrel—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00725	0.022	CbGpPWpGaD
Clopidogrel—Hypoaesthesia—Varenicline—nicotine dependence	0.00691	0.0103	CcSEcCtD
Clopidogrel—Hallucination—Varenicline—nicotine dependence	0.00691	0.0103	CcSEcCtD
Clopidogrel—Urinary tract disorder—Varenicline—nicotine dependence	0.00686	0.0102	CcSEcCtD
Clopidogrel—Oedema peripheral—Varenicline—nicotine dependence	0.00684	0.0102	CcSEcCtD
Clopidogrel—Urethral disorder—Varenicline—nicotine dependence	0.00681	0.0102	CcSEcCtD
Clopidogrel—Visual impairment—Varenicline—nicotine dependence	0.00669	0.00998	CcSEcCtD
Clopidogrel—Erythema multiforme—Varenicline—nicotine dependence	0.00657	0.00979	CcSEcCtD
Clopidogrel—Eye disorder—Varenicline—nicotine dependence	0.00649	0.00968	CcSEcCtD
Clopidogrel—Tinnitus—Varenicline—nicotine dependence	0.00647	0.00966	CcSEcCtD
Clopidogrel—Angiopathy—Varenicline—nicotine dependence	0.0063	0.0094	CcSEcCtD
Clopidogrel—Immune system disorder—Varenicline—nicotine dependence	0.00627	0.00936	CcSEcCtD
Clopidogrel—Mediastinal disorder—Varenicline—nicotine dependence	0.00626	0.00933	CcSEcCtD
Clopidogrel—Mental disorder—Varenicline—nicotine dependence	0.00608	0.00907	CcSEcCtD
Clopidogrel—Malnutrition—Varenicline—nicotine dependence	0.00605	0.00902	CcSEcCtD
Clopidogrel—Flatulence—Varenicline—nicotine dependence	0.00596	0.00888	CcSEcCtD
Clopidogrel—Back pain—Varenicline—nicotine dependence	0.00585	0.00872	CcSEcCtD
Clopidogrel—Muscle spasms—Varenicline—nicotine dependence	0.00581	0.00867	CcSEcCtD
Clopidogrel—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00559	0.017	CbGpPWpGaD
Clopidogrel—Anaemia—Varenicline—nicotine dependence	0.00559	0.00833	CcSEcCtD
Clopidogrel—Angioedema—Varenicline—nicotine dependence	0.00552	0.00824	CcSEcCtD
Clopidogrel—P2RY12—GPCR ligand binding—TAS2R16—nicotine dependence	0.00546	0.0166	CbGpPWpGaD
Clopidogrel—Vertigo—Varenicline—nicotine dependence	0.00543	0.0081	CcSEcCtD
Clopidogrel—Syncope—Varenicline—nicotine dependence	0.00542	0.00809	CcSEcCtD
Clopidogrel—Palpitations—Varenicline—nicotine dependence	0.00534	0.00797	CcSEcCtD
Clopidogrel—Loss of consciousness—Varenicline—nicotine dependence	0.00531	0.00792	CcSEcCtD
Clopidogrel—Cough—Varenicline—nicotine dependence	0.00528	0.00787	CcSEcCtD
Clopidogrel—Hypertension—Varenicline—nicotine dependence	0.00522	0.00778	CcSEcCtD
Clopidogrel—Myalgia—Varenicline—nicotine dependence	0.00515	0.00768	CcSEcCtD
Clopidogrel—Chest pain—Varenicline—nicotine dependence	0.00515	0.00768	CcSEcCtD
Clopidogrel—Arthralgia—Varenicline—nicotine dependence	0.00515	0.00768	CcSEcCtD
Clopidogrel—Anxiety—Varenicline—nicotine dependence	0.00513	0.00765	CcSEcCtD
Clopidogrel—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00511	0.00762	CcSEcCtD
Clopidogrel—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00511	0.0155	CbGpPWpGaD
Clopidogrel—CYP2B6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00504	0.0153	CbGpPWpGaD
Clopidogrel—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00499	0.0152	CbGpPWpGaD
Clopidogrel—Oedema—Varenicline—nicotine dependence	0.00493	0.00736	CcSEcCtD
Clopidogrel—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00493	0.015	CbGpPWpGaD
Clopidogrel—Infection—Varenicline—nicotine dependence	0.0049	0.00731	CcSEcCtD
Clopidogrel—Shock—Varenicline—nicotine dependence	0.00485	0.00724	CcSEcCtD
Clopidogrel—Nervous system disorder—Varenicline—nicotine dependence	0.00484	0.00722	CcSEcCtD
Clopidogrel—Skin disorder—Varenicline—nicotine dependence	0.00479	0.00715	CcSEcCtD
Clopidogrel—Hypotension—Varenicline—nicotine dependence	0.00461	0.00688	CcSEcCtD
Clopidogrel—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.0045	0.0067	CcSEcCtD
Clopidogrel—Insomnia—Varenicline—nicotine dependence	0.00446	0.00666	CcSEcCtD
Clopidogrel—Dyspnoea—Varenicline—nicotine dependence	0.0044	0.00656	CcSEcCtD
Clopidogrel—Dyspepsia—Varenicline—nicotine dependence	0.00434	0.00648	CcSEcCtD
Clopidogrel—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00433	0.0131	CbGpPWpGaD
Clopidogrel—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00427	0.013	CbGpPWpGaD
Clopidogrel—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00426	0.00635	CcSEcCtD
Clopidogrel—Fatigue—Varenicline—nicotine dependence	0.00425	0.00634	CcSEcCtD
Clopidogrel—Constipation—Varenicline—nicotine dependence	0.00422	0.00629	CcSEcCtD
Clopidogrel—Pain—Varenicline—nicotine dependence	0.00422	0.00629	CcSEcCtD
Clopidogrel—CYP2B6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00414	0.0126	CbGpPWpGaD
Clopidogrel—Feeling abnormal—Varenicline—nicotine dependence	0.00407	0.00606	CcSEcCtD
Clopidogrel—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00405	0.0123	CbGpPWpGaD
Clopidogrel—Gastrointestinal pain—Varenicline—nicotine dependence	0.00403	0.00602	CcSEcCtD
Clopidogrel—Urticaria—Varenicline—nicotine dependence	0.00392	0.00585	CcSEcCtD
Clopidogrel—Abdominal pain—Varenicline—nicotine dependence	0.0039	0.00582	CcSEcCtD
Clopidogrel—Body temperature increased—Varenicline—nicotine dependence	0.0039	0.00582	CcSEcCtD
Clopidogrel—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00386	0.0117	CbGpPWpGaD
Clopidogrel—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00381	0.0116	CbGpPWpGaD
Clopidogrel—P2RY12—G alpha (i) signalling events—OPRM1—nicotine dependence	0.0038	0.0115	CbGpPWpGaD
Clopidogrel—Hypersensitivity—Varenicline—nicotine dependence	0.00364	0.00542	CcSEcCtD
Clopidogrel—Asthenia—Varenicline—nicotine dependence	0.00354	0.00528	CcSEcCtD
Clopidogrel—P2RY12—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00353	0.0107	CbGpPWpGaD
Clopidogrel—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00352	0.0107	CbGpPWpGaD
Clopidogrel—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00351	0.0106	CbGpPWpGaD
Clopidogrel—Pruritus—Varenicline—nicotine dependence	0.00349	0.00521	CcSEcCtD
Clopidogrel—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00347	0.0105	CbGpPWpGaD
Clopidogrel—Diarrhoea—Varenicline—nicotine dependence	0.00338	0.00503	CcSEcCtD
Clopidogrel—Dizziness—Varenicline—nicotine dependence	0.00326	0.00487	CcSEcCtD
Clopidogrel—Vomiting—Varenicline—nicotine dependence	0.00314	0.00468	CcSEcCtD
Clopidogrel—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00313	0.0095	CbGpPWpGaD
Clopidogrel—Rash—Varenicline—nicotine dependence	0.00311	0.00464	CcSEcCtD
Clopidogrel—Dermatitis—Varenicline—nicotine dependence	0.00311	0.00464	CcSEcCtD
Clopidogrel—Headache—Varenicline—nicotine dependence	0.00309	0.00461	CcSEcCtD
Clopidogrel—P2RY12—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00309	0.00937	CbGpPWpGaD
Clopidogrel—P2RY12—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00302	0.00918	CbGpPWpGaD
Clopidogrel—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00301	0.00913	CbGpPWpGaD
Clopidogrel—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00297	0.00901	CbGpPWpGaD
Clopidogrel—Nausea—Varenicline—nicotine dependence	0.00293	0.00437	CcSEcCtD
Clopidogrel—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00285	0.00866	CbGpPWpGaD
Clopidogrel—P2RY12—Signaling by GPCR—TAS2R16—nicotine dependence	0.0028	0.00851	CbGpPWpGaD
Clopidogrel—P2RY12—G alpha (i) signalling events—DRD2—nicotine dependence	0.00275	0.00834	CbGpPWpGaD
Clopidogrel—P2RY12—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00255	0.00774	CbGpPWpGaD
Clopidogrel—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00244	0.0074	CbGpPWpGaD
Clopidogrel—P2RY12—GPCR downstream signaling—FGD1—nicotine dependence	0.00242	0.00735	CbGpPWpGaD
Clopidogrel—CYP2B6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00233	0.00708	CbGpPWpGaD
Clopidogrel—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00232	0.00705	CbGpPWpGaD
Clopidogrel—P2RY12—GPCR ligand binding—OPRM1—nicotine dependence	0.0023	0.00699	CbGpPWpGaD
Clopidogrel—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00229	0.00695	CbGpPWpGaD
Clopidogrel—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00228	0.00692	CbGpPWpGaD
Clopidogrel—CYP2B6—Biological oxidations—CYP2A7—nicotine dependence	0.0022	0.00668	CbGpPWpGaD
Clopidogrel—P2RY12—Signaling by GPCR—FGD1—nicotine dependence	0.0022	0.00667	CbGpPWpGaD
Clopidogrel—P2RY12—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00219	0.00663	CbGpPWpGaD
Clopidogrel—CYP2B6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00217	0.00659	CbGpPWpGaD
Clopidogrel—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.00215	0.00653	CbGpPWpGaD
Clopidogrel—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00212	0.00644	CbGpPWpGaD
Clopidogrel—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00198	0.006	CbGpPWpGaD
Clopidogrel—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00188	0.00571	CbGpPWpGaD
Clopidogrel—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.00186	0.00565	CbGpPWpGaD
Clopidogrel—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00184	0.00558	CbGpPWpGaD
Clopidogrel—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00176	0.00535	CbGpPWpGaD
Clopidogrel—P2RY12—GPCR ligand binding—DRD2—nicotine dependence	0.00166	0.00505	CbGpPWpGaD
Clopidogrel—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00166	0.00505	CbGpPWpGaD
Clopidogrel—P2RY12—Signaling Pathways—TAS2R16—nicotine dependence	0.00166	0.00502	CbGpPWpGaD
Clopidogrel—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00164	0.00498	CbGpPWpGaD
Clopidogrel—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00161	0.00488	CbGpPWpGaD
Clopidogrel—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00152	0.0046	CbGpPWpGaD
Clopidogrel—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0015	0.00454	CbGpPWpGaD
Clopidogrel—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00137	0.00417	CbGpPWpGaD
Clopidogrel—P2RY12—GPCR downstream signaling—OPRM1—nicotine dependence	0.0013	0.00395	CbGpPWpGaD
Clopidogrel—P2RY12—Signaling Pathways—FGD1—nicotine dependence	0.0013	0.00394	CbGpPWpGaD
Clopidogrel—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.0013	0.00393	CbGpPWpGaD
Clopidogrel—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00128	0.00388	CbGpPWpGaD
Clopidogrel—P2RY12—Signaling by GPCR—OPRM1—nicotine dependence	0.00118	0.00359	CbGpPWpGaD
Clopidogrel—P2RY12—Signaling Pathways—AKR1B10—nicotine dependence	0.00115	0.00348	CbGpPWpGaD
Clopidogrel—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00106	0.00322	CbGpPWpGaD
Clopidogrel—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.001	0.00303	CbGpPWpGaD
Clopidogrel—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000986	0.00299	CbGpPWpGaD
Clopidogrel—P2RY12—GPCR downstream signaling—DRD2—nicotine dependence	0.000941	0.00285	CbGpPWpGaD
Clopidogrel—P2RY12—Signaling by GPCR—DRD2—nicotine dependence	0.000854	0.00259	CbGpPWpGaD
Clopidogrel—P2RY12—Signaling Pathways—WASF2—nicotine dependence	0.000809	0.00245	CbGpPWpGaD
Clopidogrel—P2RY12—Signaling Pathways—WASF1—nicotine dependence	0.000775	0.00235	CbGpPWpGaD
Clopidogrel—P2RY12—Signaling Pathways—OPRM1—nicotine dependence	0.000698	0.00212	CbGpPWpGaD
Clopidogrel—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000593	0.0018	CbGpPWpGaD
Clopidogrel—P2RY12—Signaling Pathways—DRD2—nicotine dependence	0.000505	0.00153	CbGpPWpGaD
Clopidogrel—CYP2B6—Metabolism—CYP2A7—nicotine dependence	0.000376	0.00114	CbGpPWpGaD
Clopidogrel—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000368	0.00112	CbGpPWpGaD
Clopidogrel—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000319	0.000967	CbGpPWpGaD
Clopidogrel—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000284	0.000863	CbGpPWpGaD
Clopidogrel—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000278	0.000842	CbGpPWpGaD
Clopidogrel—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000259	0.000787	CbGpPWpGaD
Clopidogrel—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000222	0.000672	CbGpPWpGaD
Clopidogrel—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000171	0.000519	CbGpPWpGaD
